8-K: Arrowhead's Obesity Drugs Show Strong Early Results

Arrowhead Pharmaceuticals announced positive interim Phase 1/2a clinical trial results for its RNAi-based obesity therapeutics, ARO-INHBE and ARO-ALK7, demonstrating significant weight and fat reduction.

Summary

• ARO-INHBE monotherapy achieved a dose-dependent reduction in serum Activin E, with a mean maximum reduction of -85% after a single 400 mg dose and a maximum observed reduction of -94%.
• Single dose ARO-INHBE monotherapy at week 16 led to a mean visceral fat reduction of -9.9%, a mean liver fat relative reduction of -38%, and an increased total lean tissue of 3.6%.
• Two doses of ARO-INHBE monotherapy at Week 24 achieved a mean visceral fat reduction of -15.6%, adjusted for placebo.
• Two doses of ARO-INHBE (400 mg) in combination with tirzepatide (n=4) achieved approximately two-fold weight loss at week 16 (-9.4%) compared to tirzepatide alone (-4.8%, n=5) in obese patients with type 2 diabetes mellitus.
• The combination therapy also achieved an approximately three-fold reduction in fat based on week 12 MRI, with -23.2% visceral fat, -15.4% total fat, and -76.7% liver fat reduction, versus tirzepatide alone (-7.4%, -5.3%, -20% respectively, n=5).
• ARO-INHBE has been generally well tolerated as monotherapy and in combination with tirzepatide; most treatment emergent adverse events (TEAE) were mild, and no TEAEs led to study discontinuation. One serious adverse event (SAE) of limb abscess was reported but assessed as unrelated to study treatment.
• ARO-ALK7 is the first RNAi-therapeutic to show adipocyte gene target silencing in a clinical trial, achieving dose-dependent reductions in adipose ALK7 mRNA with a mean reduction of -88% at the 200 mg dose (max -94%, n=4).
• A single dose of ARO-ALK7 led to rapid dose-dependent reductions in mean visceral fat with a -14.1% reduction, adjusted for placebo, observed at Week 8.
• ARO-ALK7 has been generally well tolerated as monotherapy; most TEAEs were mild, no TEAEs led to study discontinuation, and no SAEs were reported.

Sentiment

Score: 9

Explanation: The interim clinical trial results for both ARO-INHBE and ARO-ALK7 are highly positive, demonstrating significant efficacy in weight loss and fat reduction, particularly in combination with tirzepatide and in a challenging patient population (obese with type 2 diabetes). The safety profiles appear favorable, and the successful adipocyte gene silencing by ARO-ALK7 is a significant scientific milestone. These results suggest strong therapeutic potential and validate Arrowhead's RNAi platform in cardiometabolic diseases.

Positives

• ARO-INHBE monotherapy demonstrated robust reductions in serum Activin E, visceral fat (-9.9% at week 16), and liver fat (-38%), alongside an increase in total lean tissue (3.6%).
• ARO-INHBE in combination with tirzepatide achieved approximately two-fold greater weight loss (-9.4% vs -4.8%) and three-fold greater fat reduction (visceral, total, liver) compared to tirzepatide alone in obese patients with type 2 diabetes, a population that typically responds less to incretin therapies.
• The safety profile for ARO-INHBE was favorable, with most adverse events being mild and no study discontinuations due to treatment-emergent adverse events.
• ARO-ALK7 successfully demonstrated the first-ever adipocyte gene target silencing by an RNAi therapeutic in humans, validating the TRiM™ platform's ability to target adipose-expressed genes.
• ARO-ALK7 monotherapy showed rapid and significant reductions in visceral fat (-14.1% placebo-adjusted at Week 8).
• ARO-ALK7 also exhibited a favorable safety profile, with mild adverse events and no serious adverse events reported.
• The Activin E/ALK7 pathway is a genetically validated target, and these results provide encouraging early evidence of its therapeutic potential to improve body composition and enhance weight loss.

Negatives

• One serious adverse event (SAE) of limb abscess was reported for ARO-INHBE, although it was assessed as unrelated to study treatment by both the sponsor and site investigator.
• The interim results are based on relatively small sample sizes (e.g., n=4 for ARO-INHBE combination weight loss, n=3 for MRI data in combination, n=4 for ARO-ALK7 mRNA reduction, n=4 for ARO-ALK7 visceral fat reduction), which may not be fully indicative of final results.

Risks

• Interim results of a clinical trial are not necessarily indicative of final results, and one or more clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data becomes available.
• The safety and efficacy of the company's product candidates.
• Decisions of regulatory authorities and the timing thereof.
• The duration and impact of regulatory delays in the company's clinical programs.
• The company's ability to finance its operations.
• The likelihood and timing of the receipt of future milestone and licensing fees.
• The future success of the company's scientific studies.
• The company's ability to successfully develop and commercialize drug candidates.
• The timing for starting and completing clinical trials.
• Rapid technological change in the company's markets.
• The enforcement of the company's intellectual property rights.
• Other risks and uncertainties described in the company's most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission from time to time.

Future Outlook

Arrowhead Pharmaceuticals plans to expand current studies for ARO-INHBE and ARO-ALK7 by increasing patient numbers and extending follow-up to better understand drug durability and activity out to one year. Future plans include initiating a monotherapy cohort in obese diabetic patients and additional combination cohorts with other GLP-1/GIP agonists. The company aims to initiate Phase 2b studies as soon as possible, focusing on combination therapies in obese diabetic patients and studies for maintenance therapy after GLP-1/GIP agonists are removed. Arrowhead also intends to expand its obesity pipeline with new liver and adipocyte targets, including dimers, and leverage its sc CNS platform for central targets. Key upcoming milestones include the first commercial sales of REDEMPLO in familial chylomicronemia, the first clinical readout for ARO-DIMER-PA in 2H 2026, and the readout of Phase 3 studies for plozasiran in severe hypertriglyceridemia in Q3 2026.

Management Comments

• Carel le Roux, M.D., Ph.D. stated: "The future of obesity care must acknowledge and address the different subtypes of obesity. New therapeutic approaches should focus on reducing visceral fat and combining therapies to achieve a low cardiovascular risk state and improve cardio-renal-metabolic outcomes."
• Carel le Roux, M.D., Ph.D. commented: "The interim clinical trial results announced today for Arrowheads ARO-INHBE and ARO-ALK7 show dramatic and rapid reductions in visceral fat, a key driver in metabolic diseases. Furthermore, ARO-INHBE in combination with tirzepatide almost doubled weight loss and improved multiple measures of body composition versus tirzepatide alone in patients with obesity and type 2 diabetes mellitus. This is promising and demonstrates therapeutic potential for RNAi-based targeting of the Activin E/ALK7 pathway directly in a patient population that typically loses less weight on therapy and experiences worse cardiovascular outcomes compared to non-diabetic patients. This is a clear area of high unmet need."
• James Hamilton, M.D., MBA, Chief Medical Officer and Head of R&D, noted: "While incretin-based therapies have meaningfully advanced the treatment of obesity and metabolic disease, shortcomings around loss of lean mass, tolerability related to GI effects, reduced response in patients with diabetes, and disproportional fat mass gain after cessation of therapy remains a challenge for many patients. Interim results from the Phase 1/2a studies of ARO-INHBE and ARO-ALK7 provide encouraging early evidence that targeting the Activin E/ALK7 pathway may address some of the limitations in current standard-of-care obesity treatments."
• James Hamilton, M.D., MBA, added: "The ARO-INHBE and ARO-ALK7 programs are important strategically for Arrowhead, complementing our focus and growing commercial capabilities that enable us to potentially advance multiple novel RNAi-based therapies for cardiometabolic diseases. The impressive early results announced today further demonstrate Arrowheads leadership in the design and development of potentially best-in-class RNAi-based therapies, utilizing our proprietary and differentiated Targeted RNAi Molecule (TRiMTM) platform, for liver expressed genes such as INHBE and now for adipose expressed genes such as ALK7."
• Chris Anzalone, Ph.D., President and CEO, highlighted key early findings including: "Established Safety and Tolerability of single-dose, multi-dose, and combination regimens with tirzepatide."
• Chris Anzalone, Ph.D., also noted: "Demonstrated deep and durable knockdown of Activin E and ALK7."
• Chris Anzalone, Ph.D., further stated: "Identified signals of Activin E/ALK7 pathway translation in humans."
• Chris Anzalone, Ph.D., mentioned: "Measured favorable changes in body composition."
• Chris Anzalone, Ph.D., concluded: "Showed benefit on weight loss in a specific population with unmet need."

Industry Context

The announcement positions Arrowhead's RNAi therapeutics, ARO-INHBE and ARO-ALK7, as a novel and potentially complementary approach within the rapidly expanding obesity treatment market. While incretin-based therapies like tirzepatide have significantly advanced obesity care, they have limitations such as lean mass loss, gastrointestinal side effects, and reduced efficacy in patients with type 2 diabetes. Arrowhead's focus on reducing visceral fat and targeting the Activin E/ALK7 pathway offers a differentiated mechanism of action that could address these unmet needs, particularly in the challenging type 2 diabetic patient population. This strategy aims to synergize with existing treatments and establish a new class of therapies for cardiometabolic diseases, enhancing Arrowhead's competitive standing.

Comparison to Industry Standards

• ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes, demonstrating an approximately two-fold improvement versus -4.8% on tirzepatide alone.
• The combination therapy drove robust fat reduction, including -23.2% visceral fat, -15.4% total fat, and -76.7% liver fat reduction (week 12 MRI), representing an approximately three-fold improvement in these measures versus tirzepatide alone (-7.4% visceral fat, -5.3% total fat, -20% liver fat).
• Visceral fat and liver fat reductions with ARO-INHBE (400 mg) + low-dose tirzepatide (5 mg) compare favorably with high-dose tirzepatide (15 mg) at 52 weeks in the SURPASS-3 MRI Substudy (e.g., ARO-INHBE combo: -23.2% VAT, -76.7% Liver Fat vs. TZP 15mg: -23.95% VAT, -39.59% Liver Fat).
• The enhanced weight loss and fat reduction observed with ARO-INHBE in obese patients with type 2 diabetes is particularly notable, as this patient population typically experiences less weight loss with incretin therapy compared to non-diabetic patients (e.g., SURMOUNT-2 (T2DM) showed lower weight loss percentages than SURMOUNT-1 (No T2DM) for similar tirzepatide doses at 72 weeks).

Stakeholder Impact

• Shareholders: Highly positive impact due to strong interim clinical data, validating the company's pipeline and RNAi platform, potentially leading to increased valuation and future revenue streams.
• Patients (Obese with Type 2 Diabetes): Potential for new, more effective treatment options that address limitations of current therapies, offering better weight loss and fat reduction outcomes.
• Employees: Positive impact from successful clinical progress and pipeline expansion, potentially leading to increased job security and growth opportunities.
• Competitors: Increased competitive pressure in the obesity and cardiometabolic disease market, particularly for companies developing GLP-1/GIP agonists, as Arrowhead's therapies could be used in combination or as alternatives.
• Regulatory Authorities: Will closely monitor further clinical development and safety data for these novel RNAi therapeutics.

Next Steps

• Expand current studies for ARO-INHBE and ARO-ALK7, including increasing patient numbers and extending follow-up to better understand drug durability and activity out to one year.
• Initiate a monotherapy cohort in obese diabetic patients for ARO-INHBE.
• Initiate additional combination cohorts with other GLP-1/GIP agonists for ARO-INHBE.
• Initiate Phase 2b studies as soon as possible for both candidates, which are not gated by current studies and additions.
• Conduct combination studies (tirzepatide and other GLP-1/GIP agonists) in obese diabetic patients.
• Conduct studies aimed at using these therapies as maintenance therapy after GLP-1/GIP agonists are removed.
• Expand the obesity pipeline with new liver and adipocyte targets, including dimers targeting two adipocyte or two liver targets.
• Leverage the sc CNS platform to address central targets.
• Anticipate first commercial sales of REDEMPLO in familial chylomicronemia.
• Expect ARO-DIMER-PA targeting PCSK9 and APOC3 first clinical readout in 2H 2026.
• Plozasiran Phase 3 studies in severe hypertriglyceridemia are on pace to readout in Q3 2026.

Key Dates

Recommendation

The interim Phase 1/2a clinical data for ARO-INHBE and ARO-ALK7 are exceptionally strong, demonstrating significant efficacy in weight loss and fat reduction, particularly in combination with tirzepatide and in a high-unmet-need patient population (obese with type 2 diabetes). The safety profiles appear favorable, and the successful adipocyte gene target silencing by ARO-ALK7 is a scientific breakthrough. These results validate Arrowhead's RNAi platform and position the company as a leader in developing novel cardiometabolic therapies that could complement or improve upon existing standards of care. The potential for these drugs to address limitations of current GLP-1/GIP agonists, coupled with a robust pipeline and funding into fiscal 2028, suggests substantial upside potential for the stock.

Keywords

RNAi, obesity, ARO-INHBE, ARO-ALK7, Activin E, ALK7, visceral fat, weight loss, type 2 diabetes, cardiometabolic, clinical trials, Phase 1/2a, tirzepatide, gene silencing, Arrowhead Pharmaceuticals